People who receive AstraZeneca’s COVID-19 vaccine have a slightly increased risk of bleeding problems, according to a study published June 9 in Nature Medicine. Researchers observed adults in Scotland ...

AstraZeneca AZN announced positive results from an interim analysis of the ongoing late-stage I CAN study, which evaluated its blockbuster rare disease drug Ultomiris (ravulizumab) for IgA nephropathy ...

The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the ...

AstraZeneca has scrapped an asthma program after the FLAP inhibitor flopped in a phase 2 trial. | AstraZeneca has scrapped an ...

LONDON - AstraZeneca’s COVID-19 vaccine provided strong protection against disease and complete protection against hospitalization and death across all age groups in a late-stage U.S. study, the ...

LONDON (AP) - Britain’s health chief has hailed a new study suggesting that a single dose of the Oxford-AstraZeneca COVID-19 vaccine provides a high level of protection for 12 weeks, saying it ...

The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer’s disease.

(Reuters) -AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare condition that causes a buildup of protein deposits in the body, ...

AstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy of its investigational candidate, baxdrostat, in patients with uncontrolled ...

AstraZeneca Malaysia is deepening its investment in the country's clinical research infrastructure, reinforcing its position as the top sponsor of new studies for three consecutive years. Partnering ...